Novel Studies Build Knowledge Around Myopia Management,
Presbyopia, Dry Eye, and Contact Lens Handling
ROCHESTER, N.Y., November 5, 2024—CooperVision has unveiled its broad scientific program for the 2024 American Academy of Optometry annual meeting, helping build clinical knowledge and practice around a range of topics such as myopia management, presbyopia, dry eye, and contact lens handling. The event is expected to draw thousands of eye care professionals (ECPs), researchers, educators, and students to Indianapolis this week.
“As a longstanding partner to the global eye care community, we strongly believe in conducting and sharing research that advances how ECPs work with patients to achieve the best possible outcomes,” said Francis Erard, CooperVision’s Vice President of Research & Development. “Our scientists and study collaborators are eager to discuss several of the timeliest topics in optometry, reinforcing CooperVision’s focus on developing innovative products whose clinical advantages are complemented by robust evidence.”
A worldwide leader in myopia management, the company will spotlight multiple works relating to the efficacy of its MiSight® 1 day* contact lens1 and Paragon CRT® 100 orthokeratology contact lenses2, as well as clinical practice patterns.3
Following the debut of its clariti® 1 day multifocal with Binocular Progressive System™ contact lenses earlier this year, CooperVision adds to the conversation at Academy with two studies that provide ECPs with information on multifocal fit success. A comparison with a differently designed daily disposable multifocal contact lens indicates better overall vision satisfaction with the unique Binocular Progressive System™ technology4, while another investigation highlights patient acceptance and first fit success when moving from the original clariti® multifocal to the new 3-Add lens.5
Rounding out the scientific program are a presentation from the Centre for Ocular Research & Education (CORE) that explores how symptomatic soft contact lens wearers and non-wearers can be successfully fit with Onefit™ MED scleral lenses6, and another that examines the impact of lens back vertex power and material on subjective contact lens handling,7 which can be a discontinuation driver among patients, especially neophytes.
Additional information regarding Academy 2024, which runs from November 6-9, is available at https://aaopt.org/meetings/academy-2024-indianapolis/.
* Indications for Use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
__________________________________
References:
1 Arumugam B et al. Efficacy of MiSight® 1 day dual focus lenses in controlling myopia progression in Chinese children. AAO 2024 poster presentation.
2 Jung L et al. Efficacy of OrthoK in axial inhibition: A comprehensive retrospective review of real-world patient population from UC Berkeley Myopia Control Clinic. AAO 2024 poster presentation.
3 Fromstein S et al. Clinical Practice Patterns for the Initial Management of Young Myopic Patients in Canada. AAO 2024 poster presentation.
4 Sulley A et al. Patient Acceptance of Two Daily Disposable Multifocal Contact Lenses. AAO 2024 poster presentation.
5 Vega J et al. Ease of Success Refitting Habitual Multifocal Soft Lens Wearers with a New Progressive Multifocal Lens System. AAO 2024 poster presentation.
6 Fadel D et al. Evaluation of Scleral Lenses in the Management of Dry Eye Symptoms. AAO 2024 poster presentation.
7 Read M et al. The impact of lens back vertex power and material on contact lens handling. AAO 2024 poster presentation.
# # #
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women’s health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com.
Media Contact
Mike McDougall, APR, Fellow PRSA, FAAO
McDougall Communications for CooperVision
mike@mcdougallpr.com or +1.585.545.1815